Nebivolol Accord (Nebivolol Hydrochloride)

Nebivolol, the active ingredient in Nebivolol Accord, is a beta blocker presented as an oral dosage form for oral use. It treats hypertension in adult patients by lowering elevated blood pressure.

GNH USA supplies Nebivolol Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Nebivolol is a selective β1‑adrenergic antagonist used primarily in the management of arterial hypertension and related cardiovascular conditions. - Hypertension: reduces systolic and diastolic blood pressure in patients with essential hypertension. - Heart failure with reduced ejection fraction: improves cardiac output and may reduce hospitalization risk. - Left ventricular hypertrophy: may slow progression of structural heart changes associated with high blood pressure.

Nebivolol may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Headache: mild to moderate intensity. - Dizziness or light‑headedness, especially after standing. - Fatigue or tiredness. - Bradycardia: slower than normal heart rate. - Nausea or mild gastrointestinal upset. - Nasal congestion.

Serious or Rare Side Effects: - Severe bradycardia or heart block requiring medical attention. - Acute bronchospasm in patients with asthma or COPD. - Allergic reactions such as rash, itching, or angioedema. - Hepatic dysfunction or elevated liver enzymes. - Marked hypotension leading to syncope. - Cardiovascular collapse in overdose.

Before initiating Nebivolol therapy, clinicians should consider several safety measures. - Monitor blood pressure: ensure adequate control and avoid excessive drops. - Assess cardiac function: evaluate heart rate and ECG for bradyarrhythmias. - Use caution in asthma or chronic obstructive pulmonary disease: risk of bronchospasm. - Avoid abrupt discontinuation: taper dose to prevent rebound hypertension. - Adjust dose in renal impairment: consider reduced clearance. - Store at ambient temperature: keep in original packaging, protect from moisture and direct sunlight.

Nebivolol can interact with other medicines, altering its efficacy or safety profile. Major Interactions (Avoid): - Other beta‑blockers: additive bradycardia and hypotension. - Calcium channel blockers (verapamil, diltiazem): increased risk of AV block. - Strong CYP2D6 inhibitors (paroxetine, fluoxetine): elevated Nebivolol plasma levels. Moderate Interactions (Monitor Closely): - NSAIDs: may blunt antihypertensive effect. - Diuretics: potential for excessive blood pressure reduction. - ACE inhibitors or ARBs: monitor for additive hypotensive effect. - Clonidine: risk of rebound hypertension if stopped abruptly.